Alleviant ALLAY-HF Study
Heart Failure
About this trial
This is an interventional treatment trial for Heart Failure
Eligibility Criteria
Inclusion Criteria: Symptomatic HFpEF/HFmrEF with LVEF greater than or equal to 40% NYHA Class II, III or ambulatory IV Exercise right heart catheterization* Elevated left atrial pressure during exercise right heart catheterization (greater than or equal to 25 mmHg) Exercise PVR < 1.8 WU Ongoing stable GDMT Exclusion Criteria: Advanced heart failure Presence of a pacemaker Evidence of right heart dysfunction
Sites / Locations
- University of Alabama
- Arizona Cardiovascular Research Center
- Honor Health
- Pima Heart and Vascular
- Scripps Clinical Research Services
- San Francisco VA
- University of California San Francisco
- Santa Barbara Cottage Hospital
- The Cardiac and Vascular Institute (TCAVI)
- University of Florida Jacksonville
- HCA Florida Memorial Hospital
- NCH Research Institute
- Advent Health Orlando
- Ascension Sacred Heart
- Atlanta VA Health Care System
- Midwest Cardiovascular Institute
- Prairie Education and Research Cooperative
- St. Elizabeth Healthcare
- Cardiovascular Institute of the South
- University Medical Center New Orleans
- Boston Medical Center
- Steward St. Elizabeth's Medical Center
- VA Ann Arbor
- Ascension St. John Hospital
- Minneapolis Heart Institute Foundation
- The Valley Hospital
- VA NY Harbor Healthcare System
- New York University
- Lenox Hill Hospital
- St. Francis Hospital
- Mission Hospital
- Duke University Hospital
- The MetroHealth System
- Cleveland Clinic
- Mount Carmel Health System
- ProMedica Toledo Hospital
- South Oklahoma Heart Research, LLC.
- Providence St. Vincent's Medical Center
- Pinnacle Health Cardiovascular Institute
- Prisma Health - Midlands
- Monument Health
- Stern Cardiovascular Foundation
- Hendrick Health
- Austin Heart
- UT Southwestern
- Texas Tech University Health Sciences Center
- Baylor Scott & White Research Institute
- NextStage Clinical Research
- Medizinische Universität Graz
- OLV Hospital
- AZ Sint Jan Brugge
- Centre hospitalier de l'Universite de Montreal (CHUM)
- Centre Integre Universitaire de Sainte et de Services Scoiiaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS)
- Tbilisi Heart and Vascular
- Heart and Vascular Center-Bad Bevensen
- St. Johannes Hospital
- University of Gießen
- Marienkrankenhaus
- Askelepios Klinik Altona
- St. Vincentius Kliniken
- Universitatsklinikum Schleswig-Holstein (UKSH)
- Universitätsklinikum Kardiologie
- Universitatsmedizin Rostock
- European Interbalken Medical Center
- Shaare Zedek Medical Center
- Tel Aviv Sourasky Medical Center
- Shamir Medical Center
- Instituto Auxologico Italiano
- Poznan University of Medical Sciences
- 4th Military Hospital
- Uniwesytecki Szpital Kliniczny
- Silesian Center for Heart Disease
- Hospital de la Santa Creu i Sant Pau
- Barcelona Hospital del Mar
- Hospital Clinic de Barcelona
- Germans Trias i Pujol
- Cadiz Hospital Universitario Puerta del Mar
- Hospital Universitario Puerta de Hierro
- Valencia Hospital Clinico
Arms of the Study
Arm 1
Arm 2
Experimental
Sham Comparator
Treatment
Control
Subjects randomized to the treatment arm will undergo cardiac imaging, femoral vein access and receive the Alleviant ALV1 System device procedure.
Subjects randomized to the control arm will undergo cardiac imaging and sheath placement in femoral vein.